Adalimumab for sight-threatening uveitis in Behçet's disease

Eye

Volumn 21, Issue 6, 2007, Pages 824-825

  Mushtaq, B ^a   Saeed, T ^a   Situnayake, R D ^a   Murray, P I ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BEHCET DISEASE; CASE REPORT; DRUG MEGADOSE; DRUG SUBSTITUTION; FEMALE; HUMAN; LASER COAGULATION; MALE; RETINA MACULA CYSTOID EDEMA; TREATMENT OUTCOME; UVEITIS;

EID: 34250366261     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702352     Document Type: Article

References (6)

1. Murray PI, Sivaraj RR. Anti-TNF-α therapy for uveitis: Behçet and beyond. Eye 2005; 19: 831-833.
2. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358: 295-296.
3. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004; 31: 1362-1368.
4. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004; 138: 648-650.
5. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123: 903-912.
6. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: An open-label trial. Arthr Rheum 2005; 52: 2478-2484.